Organon & Co. - OGN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $22.60
  • Forecasted Upside: 6.10%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$21.30
▲ +0.42 (2.01%)

This chart shows the closing price for OGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organon & Co. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGN

Analyst Price Target is $22.60
▲ +6.10% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Organon & Co. in the last 3 months. The average price target is $22.60, with a high forecast of $28.00 and a low forecast of $19.00. The average price target represents a 6.10% upside from the last price of $21.30.

This chart shows the closing price for OGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Organon & Co.. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$18.00 ➝ $20.00Low
4/29/2024Piper SandlerBoost TargetOverweight ➝ Overweight$22.00 ➝ $24.00Low
2/20/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$16.00 ➝ $18.00Low
11/22/2023Piper SandlerLower TargetOverweight ➝ Overweight$32.00 ➝ $22.00Low
11/3/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$33.00 ➝ $16.00Low
10/25/2023Piper SandlerLower TargetOverweight ➝ Overweight$33.00 ➝ $32.00Low
10/12/2023Bank of AmericaLower Target$23.00 ➝ $19.00Low
10/11/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$27.00 ➝ $22.00Low
9/21/2023BarclaysInitiated CoverageOverweight$28.00Low
8/9/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$25.00 ➝ $27.00Low
3/15/2023Raymond JamesInitiated CoverageOutperform$33.00Low
11/4/2022Morgan StanleyLower TargetEqual Weight$27.00 ➝ $24.00Low
10/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$25.00Low
10/12/2022Morgan StanleyLower TargetEqual Weight$35.00 ➝ $27.00Low
9/6/2022Piper SandlerUpgradeNeutral ➝ Overweight$37.00 ➝ $34.00Low
8/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$40.00 ➝ $37.00Low
7/8/2022Morgan StanleyLower TargetEqual Weight$35.00 ➝ $34.00N/A
4/27/2022The Goldman Sachs GroupInitiated CoverageBuy$40.00Medium
4/6/2022Morgan StanleyLower TargetEqual Weight$37.00 ➝ $35.00Low
2/22/2022Morgan StanleyBoost TargetEqual Weight$35.00 ➝ $37.00Low
10/7/2021Piper SandlerInitiated CoverageNeutral$35.00Low
9/1/2021Bank of AmericaInitiated CoverageBuy$43.00Low
8/18/2021CitigroupBoost TargetBuy$35.00 ➝ $43.00High
8/16/2021Morgan StanleyBoost TargetEqual Weight$33.00 ➝ $35.00Low
7/22/2021CitigroupInitiated CoverageBuy$35.00Medium
6/15/2021JPMorgan Chase & Co.Initiated CoverageNeutral$38.00Medium
6/11/2021Morgan StanleyInitiated CoverageEqual Weight$33.00Medium
6/10/2021Evercore ISIInitiated CoverageOutperformHigh
6/3/2021CowenInitiated CoverageMarket Perform$40.00Low
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$35.00Low
6/2/2021Truist FinancialInitiated CoverageBuy$48.00Low
(Data available from 7/15/2019 forward)

News Sentiment Rating

1.52 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/18/2023
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 16 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/16/2024
  • 23 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 10 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/16/2024
  • 18 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/16/2024
  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/15/2024
  • 11 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 11 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Organon & Co. logo
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Read More

Today's Range

Now: $21.30
Low: $20.82
High: $21.44

50 Day Range

MA: $20.78
Low: $19.92
High: $21.96

52 Week Range

Now: $21.30
Low: $10.84
High: $24.08

Volume

1,962,200 shs

Average Volume

2,339,614 shs

Market Capitalization

$5.48 billion

P/E Ratio

5.21

Dividend Yield

5.26%

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Organon & Co.?

The following Wall Street research analysts have issued research reports on Organon & Co. in the last twelve months: Bank of America Co., Barclays PLC, Morgan Stanley, Piper Sandler, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for OGN.

What is the current price target for Organon & Co.?

5 Wall Street analysts have set twelve-month price targets for Organon & Co. in the last year. Their average twelve-month price target is $22.60, suggesting a possible upside of 6.1%. Barclays PLC has the highest price target set, predicting OGN will reach $28.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $19.00 for Organon & Co. in the next year.
View the latest price targets for OGN.

What is the current consensus analyst rating for Organon & Co.?

Organon & Co. currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OGN.

What other companies compete with Organon & Co.?

How do I contact Organon & Co.'s investor relations team?

Organon & Co.'s physical mailing address is 2000 Galloping Hill Road, Kenilworth, New Jersey 07033. The company's listed phone number is 551-430-6900 and its investor relations email address is [email protected]. The official website for Organon & Co. is www.organon.com. Learn More about contacing Organon & Co. investor relations.